Iron indices: What do they really mean?

Slides:



Advertisements
Similar presentations
Stephen P. McDonald, Graeme R. Russ  Kidney International 
Advertisements

Kamyar Kalantar-Zadeh  Kidney International 
A.M. Thompson, T.G. Pickering  Kidney International 
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Beta blockers in the management of chronic kidney disease
A. Besarab  Kidney International  Volume 69, Pages S13-S18 (May 2006)
New options for the anemia of chronic kidney disease
Volume 70, Issue 8, Pages (October 2006)
Iron status and iron supplementation in peritoneal dialysis patients
Anemia management in chronic kidney disease
End-stage renal disease in developing countries
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients  G.A. Block, P. Raggi, A. Bellasi, L. Kooienga,
Volume 80, Issue 10, Pages (November 2011)
Volume 54, Issue 2, Pages (August 1998)
Volume 62, Issue 2, Pages (August 2002)
Overcoming barriers that inhibit proper treatment of anemia
Kamyar Kalantar-Zadeh  Kidney International 
Chapter 2: Use of iron to treat anemia in CKD
Volume 76, Pages S50-S99 (August 2009)
Volume 70, Pages S21-S25 (December 2006)
Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?  Fu L. Luan, Diane E. Steffick,
Volume 68, Issue 6, Pages (December 2005)
Comorbidity and confounding in end-stage renal disease
D. Batlle, P. Ramadugu, M.J. Soler  Kidney International 
A new era in phosphate binder therapy: What are the options?
Proinflammatory effects of iron sucrose in chronic kidney disease
Volume 70, Issue 11, Pages (December 2006)
Joseph W. Eschbach, John W. Adamson  Kidney International 
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Edmund G. Lowrie  Kidney International 
Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott 
Volume 73, Pages S5-S17 (April 2008)
Volume 70, Issue 12, Pages (December 2006)
Blood pressure targets in hemodialysis patients
Volume 69, Issue 10, Pages (May 2006)
Fructose intake as a risk factor for kidney stone disease
Recent experience with high-dose intravenous iron administration
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Microbiology and outcomes of peritonitis in North America
Volume 71, Issue 6, Pages (March 2007)
Counteracting progression of renal disease: A look into the future
Rajnish Mehrotra, Joel D. Kopple, Marsha Wolfson  Kidney International 
Volume 71, Issue 4, Pages (February 2007)
Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis  N.-Y. Zalunardo, C.-L. Rose, I.W.Y.
Volume 67, Issue 6, Pages (June 2005)
Connections between vascular calcification and progression of chronic kidney disease: Therapeutic alternatives  Keith A. Hruska, Suresh Mathew, Matthew.
Stephen P. McDonald, Graeme R. Russ  Kidney International 
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients  B. Bammens, P. Evenepoel, H. Keuleers,
Daily nocturnal home hemodialysis
K. Kalantar-Zadeh, J. D. Kopple, N. Kamranpour, A. M. Fogelman, M
Organ transplantation goes to the movies
Volume 63, Issue 2, Pages (February 2003)
Volume 70, Issue 8, Pages (October 2006)
Volume 72, Issue 2, Pages (July 2007)
Volume 55, Pages S3-S16 (June 1999)
Is it the low-protein diet or simply the salt restriction?
Internet Organ Solicitation, Explained
Volume 70, Issue 7, Pages (October 2006)
Charles A. Herzog  Kidney International 
Volume 71, Issue 9, Pages (May 2007)
Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation  A.K. Singh, D.W. Coyne,
Volume 70, Issue 5, Pages (September 2006)
Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance1  William M.
Strategies for iron supplementation: Oral versus intravenous
The International Pediatric Peritonitis Registry: Starting to walk
E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins 
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Decision-Making in Patients With Cancer and Kidney Disease
Characteristics of sudden death in hemodialysis patients
Presentation transcript:

Iron indices: What do they really mean? D. Coyne  Kidney International  Volume 69, Pages S4-S8 (May 2006) DOI: 10.1038/sj.ki.5000404 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 Graph illustrating the association between malnutrition scores and serum ferritin levels. Patients considered to have severe protein-energy malnutrition had significantly higher serum ferritin levels than patients with moderate protein-energy malnutrition (PEM) or adequately nourished patients. Reprinted with permission from Nephrol Dial Transplant 2004; 19: 141–149.14 Kidney International 2006 69, S4-S8DOI: (10.1038/sj.ki.5000404) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 Hazard ratios of death for time-varying ferritin categories. In unadjusted model, a serum ferritin >800 ng/ml during each quarter was associated with increased death rate, whereas in case-mix adjusted model, a tendency toward increased death rate first was observed when serum ferritin was >1000 ng/ml. After additional multivariate adjustment for the confounding effect of malnutrition–inflammation–cachexia syndrome (MICS), there was no increased death rate for serum ferritin levels as high as 1200 ng/ml. Reprinted with permission from J Am Soc Nephrol 2005; 16: 3070–3080.18 Kidney International 2006 69, S4-S8DOI: (10.1038/sj.ki.5000404) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 Response to continued i.v. iron therapy (50–100 mg/week) in 149 hemodialysis patients who were already considered iron replete based on serum ferritin levels. These patients responded to i.v. iron with increases in mean hematocrit levels (a) and an enhanced response to recombinant human erythropoietin therapy, despite having serum ferritin levels above the Kidney Disease Outcomes Quality Initiative-recommended range (b). Reprinted with permission from Clin Nephrol 2002; 57: 136–141.29 Kidney International 2006 69, S4-S8DOI: (10.1038/sj.ki.5000404) Copyright © 2006 International Society of Nephrology Terms and Conditions